Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor
NCT ID: NCT03939403
Last Updated: 2021-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
180 participants
INTERVENTIONAL
2019-11-18
2021-05-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This a controlled randomized clinical study and 180 patients will be recruited (90 per arm) and the primary study outcome is the number of obtained oocytes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Follicular Phase Stimulation vs. Luteal Phase Stimulation in Patients Diagnosed With Suboptimal Response
NCT03939390
Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa
NCT03555942
Corifollitropin Alfa on D5 Versus D7 After Contraceptive Pill
NCT02490150
Continuous Double Ovarian Stimulation.
NCT05815719
Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)
NCT06193135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
7-days pill free interval
Time of administration of Corifollitropin Alfa
The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.
The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.
The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use.
5-days pill free interval
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Time of administration of Corifollitropin Alfa
The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.
The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.
The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 32 years old
* BMI \>18 and \<30
* Antral follicle count \>12 (summing both ovaries)
* Presence of both ovaries
* Ability to participate in and comply with study protocol
* Signed informed consent
* No treatment with ovulation stimulators in the 3 months prior to the start of stimulation.
Exclusion Criteria
* AFC \>20
* Polycystic ovary syndrome
* Concurrent participation in another study
18 Years
32 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Bernabeu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joaquín Llácer
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Bernabeu
Alicante, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IB-0319-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.